Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors, EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic, WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers, MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss) and the tag subtype-page.
Shares MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss), Lynch syndrome, Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag subtype-page.
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tag subtype-page.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag subtype-page.
Shares CTLA-4, BRAF, Ipilimumab, Nivolumab and the tag subtype-page.
Shares Dostarlimab, Histopathology & immunohistochemistry, Pembrolizumab, Immune checkpoint inhibitors and the tag subtype-page.
Shares BRAF, Atezolizumab, Nivolumab, Pembrolizumab and the tag subtype-page.
Shares MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss), Dostarlimab, Pembrolizumab and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.